Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top

Investigational New Drugs

Issue Special Issue 1/2010

Content (7 Articles)

Open Access SPECIAL ISSUE ARTICLE

The deacetylase inhibitors—here to stay!

H. Miles Prince

Open Access SPECIAL ISSUE ARTICLE

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

Michael Dickinson, Ricky W. Johnstone, H. Miles Prince

Open Access SPECIAL ISSUE ARTICLE

Histone deacetylase inhibitors in Hodgkin lymphoma

Daniela Buglio, Anas Younes

Open Access SPECIAL ISSUE ARTICLE

The DAC system and associations with multiple myeloma

Enrique M. Ocio, Jesús F. San Miguel

Open Access SPECIAL ISSUE ARTICLE

The DAC system and associations with acute leukemias and myelodysplastic syndromes

Gesine Bug, Oliver G. Ottmann

Open Access SPECIAL ISSUE ARTICLE

Deactylase inhibition in myeloproliferative neoplasms

Sridurga Mithraprabhu, George Grigoriadis, Tiffany Khong, Andrew Spencer

Open Access SPECIAL ISSUE ARTICLE

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

Jasmine Zain, Owen A. O’Connor

Dec 10
Issue: 6/2010
Feb 11
Issue: 1/2011

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits